Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22016213 | 0.85 | MAPT (0.40) | AAK1MAPTNAMPTSRCBTK | |
| SCHEMBL24312244 | 0.78 | MAPT (0.41) | AAK1MAPTNAMPTBTKKDM5A | |
| SCHEMBL22016173 | 0.74 | BRD1 (0.41) | AAK1SRCBTK | |
| SCHEMBL24312103 | 0.73 | HASPIN (0.44) | MAPTNAMPTGABRA5QRFPRTOP2A | |
| SCHEMBL29856207 | 0.69 | MAPT (0.44) | MAPTNAMPTQRFPRTOP2A | |
| SCHEMBL14327804 | 0.69 | MAPT (0.44) | MAPTNAMPTAOC3TOP2A | |
| SCHEMBL29856743 | 0.69 | MAPT (0.44) | MAPTNAMPTAOC3TOP2A | |
| SCHEMBL20313755 | 0.69 | NR3C1 (0.40) | — | |
| SCHEMBL35211579 | 0.69 | KDM4E (0.48) | MAPTNAMPTQRFPRTOP2A | |
| SCHEMBL24925368 | 0.68 | RORC (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | AAK1 3444/4885MAPT 949/4885CRHR1 3329/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | AAK1 3444/4885MAPT 949/4885CRHR1 3329/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | AAK1 3444/4885MAPT 949/4885CRHR1 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.